Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
- COMMENTARY／Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
- SURVEY／RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
- COMMENTARY／JSHP to Promote Use of Generics
June 8, 2009
- COMMENTARY／Combination Drugs Becoming a "Boom"
June 1, 2009
- COMMENTARY／Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
- COMMENTARY／Why Does the Use of Generics Not Increase?
April 27, 2009
- EMTs Allowed to Administer Epipen
April 27, 2009
- COMMENTARY／Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
- The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
- COMMENTARY／Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
- Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
- COMMENTARY／Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
- COMMENTARY／National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
- Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
- Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
- Paltac/Alfresa Merger Plan Canceled, but Distribution Reform Remains to Be Done
February 2, 2009
- COMMENTARY／Industry Should Guarantee Development of Innovative Drugs and Use of More Generics
January 19, 2009
- COMMENTARY／Aiming at Further Growth beyond Global Recession
January 12, 2009
- COMMENTARY／Rule to Restrict Participation in CDFS Committee Deliberations Needs Continued Validation
January 5, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…